Selected article for: "drug design and novel coronavirus"

Author: Sivasankarapillai, Vishnu Sankar; Pillai, Akhilash M.; Rahdar, Abbas; Sobha, Anumol P.; Das, Sabya Sachi; Mitropoulos, Athanasios C.; Mokarrar, Mahboobeh Heidari; Kyzas, George Z.
Title: On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges
  • Cord-id: kx6asglb
  • Document date: 2020_4_28
  • ID: kx6asglb
    Snippet: Global health is facing the most dangerous situation regarding the novel severe acute respiratory syndrome called coronavirus 2 (SARS-CoV-2), which is widely known as the abbreviated COVID-19 pandemic. This is due to the highly infectious nature of the disease and its possibility to cause pneumonia induced death in approximately 6.89% of infected individuals (data until 27 April 2020). The pathogen causing COVID-19 is called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is
    Document: Global health is facing the most dangerous situation regarding the novel severe acute respiratory syndrome called coronavirus 2 (SARS-CoV-2), which is widely known as the abbreviated COVID-19 pandemic. This is due to the highly infectious nature of the disease and its possibility to cause pneumonia induced death in approximately 6.89% of infected individuals (data until 27 April 2020). The pathogen causing COVID-19 is called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is believed to be originated from the Wuhan Province in China. Unfortunately, an effective and approved vaccine for SARS-CoV-2 virus is still not available, making the situation more dangerous and currently available medical care futile. This unmet medical need thus requires significant and very urgent research attention to develop an effective vaccine to address the SARS-CoV-2 virus. In this review, the state-of-the-art drug design strategies against the virus are critically summarized including exploitations of novel drugs and potentials of repurposed drugs. The applications of nanochemistry and general nanotechnology was also discussed to give the status of nanodiagnostic systems for COVID-19.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute lung injury: 1, 2, 3, 4
    • ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • ace inhibitor and acute respiratory distress syndrome ards: 1, 2, 3, 4
    • ace inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace related enzyme and active site: 1
    • ace related enzyme and acute lung injury: 1
    • ace related enzyme and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • acid detection and acute chronic: 1
    • acid detection and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • acid detection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid sample and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid sample and adjunctive therapy: 1
    • action different mechanism and acute respiratory distress syndrome: 1
    • action different mechanism and acute respiratory distress syndrome ards: 1
    • action different mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • activator transcription factor and acute chronic: 1, 2, 3
    • activator transcription factor and acute lung injury: 1, 2, 3, 4, 5
    • activator transcription factor and acute lung injury cause: 1
    • activator transcription factor and acute respiratory distress syndrome: 1, 2, 3, 4, 5